Texas Fertility Center presents an independent study supporting the ERA® test as a method to improve pregnancy rates at the recent American Society for Reproductive Medicine (ASRM) meeting in San Antonio, Texas
Researchers from Texas Fertility Center, a clinic specialized in providing advanced infertility and reproductive endocrinology services, presented a total of 5 studies at ASRM 2017 in San Antonio, TX, about different topics ranging from endometrial receptivity to embryo culture, all linked by the main topic of assisted reproductive technology (ART).
One of these studies was focused on the use of the ERA® test, a diagnostic test designed, developed and patented by IGENOMIX in 2009 (PCT/ES2009/000386). The ERA® test helps to evaluate a woman’s endometrial receptivity through genetic analysis of a biopsy of the endometrial lining identifying a patient’s unique “window of implantation” (WOI) leading to a personalized embryo transfer (pET).
Researchers followed 85 women between the ages of 27 and 51 who underwent medicated frozen embryo transfer (FET) cycles. The goal was to assess ERA® test as a predictor of pregnancy in FET cycles. The results of the study showed that women who underwent this test were significantly more likely to have a receptive endometrium, according to ERA® testing, on the seventh day of progesterone – rather than on the sixth day as previously thought. Additionally, women who underwent a transfer on the seventh day of progesterone in medicated FET cycles had higher pregnancy rates.
Click here to see the poster.
About Texas Fertility Center (TFC)
Texas Fertility Center (TFC) has been recognized in the USA for outstanding pregnancy rates, leading-edge laboratory procedures and innovative research programs as a provider of advanced infertility and reproductive endocrinology services.
IGENOMIX is a biotechnology company that provides advanced services in genetic reproduction. It has a wealth of experience and advanced research capabilities that has made this company one of the world leaders in its field, enabling it to provide effective solutions tailored to different infertility problems. The company has a presence in Miami, Los Angeles and New York, and 11 more labs in the rest of the world.